rethinkPeptides Search
Menu
Study breakdown

How the Body's Natural Defense Peptides Block Gene Therapy Viruses

LaboratoryLow Moderate evidence
The takeaway

Human alpha-defensins HNP1 and HD5 neutralize AAV gene therapy vectors through distinct mechanisms — one blocks cell binding, the other acts post-binding.

2 mechanisms

HD5 blocks AAV cell binding while HNP1 neutralizes AAV after it has already attached to cells

What the researchers found

HD5 prevents AAV cell binding while HNP1 neutralizes AAV post-binding — two distinct innate immune mechanisms that limit gene therapy efficacy.

Why it matters

Understanding how defensins block AAV helps design gene therapy vectors that evade innate immunity, improving treatment success rates.

The numbers in context

Both HNP1 and HD5 inhibit AAV2 and AAV6 at low micromolar concentrations; block VP1 unique domain externalization; prevent nuclear entry.

How the study worked

In vitro AAV infection assays with purified human defensins HNP1 and HD5, measuring binding, entry, and infection of AAV2 and AAV6.

Who was studied

N/A (cell culture with human alpha-defensins and AAV vectors)

What this study cannot tell us

In vitro study — defensin concentrations in relevant tissues in vivo may differ. Only AAV2 and AAV6 serotypes tested.

How to read the evidence

In vitro mechanistic study — high scientific rigor for understanding defensin-AAV interactions, limited direct clinical translatability.

When this study was published

Published in 2025 in PLoS Pathogens, advancing understanding of innate immune barriers to gene therapy.

The bigger picture

Overcoming both adaptive and innate immune barriers is essential for gene therapy to reach its full clinical potential.

Questions still open

  • Can AAV vectors be engineered to resist defensin neutralization?
  • Do defensin levels explain patient-to-patient variability in gene therapy efficacy?

Common questions

Why does the immune system attack gene therapy?
Natural defense peptides called defensins can neutralize the AAV viruses used to deliver gene therapy, reducing treatment effectiveness.
Can gene therapy be improved to overcome defensins?
Understanding exactly how defensins block AAV — as this study reveals — could guide engineering of AAV vectors that resist neutralization.

Read the original research

Mechanisms of AAV neutralization by human alpha-defensins.

PLoS pathogens, 21(7), e1013283

Citation

Porter, Jessica M; Hulce, Kaitlin R; Oswald, Mackenzi S; Busuttil, Kevin; Emmanuel, Shanan N; Bennett, Antonette; McKenna, Robert; Smith, Jason G. (2025). Mechanisms of AAV neutralization by human alpha-defensins.. PLoS pathogens, 21(7), e1013283. https://doi.org/10.1371/journal.ppat.1013283